Eli Lilly and Company (NYSE:LLY) Stock Position Lessened by InTrack Investment Management Inc

InTrack Investment Management Inc lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 11.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,470 shares of the company’s stock after selling 730 shares during the period. Eli Lilly and Company accounts for approximately 2.1% of InTrack Investment Management Inc’s portfolio, making the stock its 6th largest holding. InTrack Investment Management Inc’s holdings in Eli Lilly and Company were worth $2,565,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Silicon Valley Capital Partners purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $25,000. Bogart Wealth LLC lifted its stake in shares of Eli Lilly and Company by 193.3% during the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after buying an additional 58 shares during the period. Laffer Tengler Investments purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $33,000. Raleigh Capital Management Inc. raised its stake in Eli Lilly and Company by 156.4% during the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after purchasing an additional 61 shares during the period. Finally, Tanglewood Legacy Advisors LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $37,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on LLY. Truist Financial increased their price target on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Barclays increased their price target on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 9th. Jefferies Financial Group raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price target for the stock from $408.00 to $615.00 in a research note on Tuesday, August 8th. Finally, UBS Group increased their price target on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the stock a “buy” rating in a research note on Wednesday, May 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Trading Down 1.2 %

NYSE LLY opened at $591.77 on Friday. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $601.84. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The company has a market capitalization of $561.76 billion, a price-to-earnings ratio of 82.30, a price-to-earnings-growth ratio of 2.47 and a beta of 0.32. The company’s fifty day moving average price is $507.52 and its two-hundred day moving average price is $434.64.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the prior year, the firm posted $1.25 EPS. The firm’s revenue was up 28.1% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were given a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company’s payout ratio is currently 62.87%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 591 shares of the firm’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $466.62, for a total transaction of $275,772.42. Following the transaction, the insider now owns 101,028,219 shares of the company’s stock, valued at approximately $47,141,787,549.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 591 shares of the firm’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $466.62, for a total transaction of $275,772.42. Following the transaction, the insider now owns 101,028,219 shares of the company’s stock, valued at approximately $47,141,787,549.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now directly owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. Insiders have sold a total of 1,010,309 shares of company stock worth $21,095,701,670 in the last ninety days. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.